Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2004-01-16
2011-11-01
Lundgren, Jeffrey S. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S562000
Reexamination Certificate
active
08048923
ABSTRACT:
The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain α-keto acids. In particular, the present invention relates to the treatment or prevention of Huntington's disease and other polyglutamine disorders caused by expanded genomic CAG nucleotides.
REFERENCES:
patent: 2002/0173537 (2002-11-01), Feurerstein et al.
Hertz et al., “Astrocytes:Glutamate Producers for Neurons”, Journal of Neuroscience Research, 57:417-428 (1999).
Apostol et al., “A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation inDrosophila”, Proceedings of the National Academy of Sciences May 13, 2003 100 (10):5950-5955.
Swanson et al., “Methionine Sulfoximine Reduces Cortical Infarct Size in Rats After Middle Cerebral Artery Occlusion”, Stroke, vol. 21, No. 2, Feb. 1990, pp. 322-327.
Lamar et al., “The duration of the inhibition of glutamine synthetase by methionine sulfoximine”, Biochemical Pharmacology, vol. 17, pp. 636-640, 1968.
Takahashi et al., “Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats”, The American Physiological Society, 1991, pp. H825-H829.
Hack et al., “Glufosinate Ammonium-Some aspects of its mode of action in mammals”, FD CHEM.Toxic., vol. 32; No. 5, pp. 461-470, 1994.
Gill et al., “The crystal structure of phosphinothricin in the active site of glutamine synthetase Illuminates the Mechanism of Enzymatic Inhibition”, Biochemistry 2001, 40, 1903-1912.
Blei, Andres T., et al., “Ammonia-Induced Brain Edema and Intracranial Hypertension in Rats After Portacaval Anastomosis,”Hepatology19(6):,1437-1444, Jun. 1994.
Brusilow, Saul W. “Inborn Errors of Urea Synthesis,”In: Scriver CR, Lloyd Jk, eds. Genetic and Metabolic Disease in Pediatrics. 5: 140-165, London: Butterworths, 1985.
Brusilow, Saul W., et al., “Urea Cycle Disorders: Diagnosis, Pathophysiology, and Therapy,”Advances in Pediatrics43:127-170, 1996.
Butterworth, R.F., “Effects of Hyperammonaemia on Brain Function,”J. Inher. Metab. Dis. 21(1):6-20, 1998.
Cordoba, Juan, et al., “Brain Edema and Hepatic Encephalopathy,”Seminars in Liver Disease16(3): 271-280, 1996.
Folbergrova, J., “Free Glutamine Level in the Rat Brain in Vivo After Methionine Sulphoximine Administration,”Physiologia Bohemoslovenica13:21-26, 1963.
Gershoff, S.N., et al.,“The Relative Effect of Methionine Sulfoximine on Different Animal Species,”J. Nutr. 45:451-458, 1951.
Häussinger, Dieter, et al.,“Pathogenesis of Hepatic Encephalopathy,”Journal of Gastroenterology and Hepatology17:5256-S259, 2002.
Hawkins, Richard, et al., “Effect of Reducing Brain Glutamine Synthesis on Metabolic Symptoms of Hepatic Encephalopathy,”Journal of Neurochemistry60(3):1000-1006, 1993.
Hawkins, Richard, et al., “Hyperammonaemia Does Not Impair Brain Function in the Absence of Net Glutamine Synthesis,”Biochem. J. 277:697-703, 1991.
Hirata, Takahiko, et al., “Impaired Pial Arteriolar Reactivity to Hypercapnia During Hyperammonemia Depends on Glutamine Synthesis,”Stroke27(4): 729-736, 1996.
Jonung, Torbjorn, et al., “Methionine Sulfoximine Prevents the Accumulation of Large Neutral Amino Acids in Brain of Hyperammonemic Rats,”J. Surgical Research36:349-353, 1984.
Krakoff, Irwin H., et al., “Effect of Methionine Sulfoximine in Man,”J. Pharm. Experimenetal Ther. 2:599-604, 1961.
Lamar, C., et al., “The Duration of the Inhibition of Glutamine Synthetase by Methionine Sulfoximine,”Biochemical Pharmacology17:636-642, 1968.
Master, Sonali, et al., “Cerebral Blood Flow and the Development of Ammonia-Induced Brain Edema in Rats After Portacaval Anastomosis,”Hepatology30(4): 876-880, 1999.
Norenberg, Michael D., et al,“Fine Structural Localization of Glutamine Synthetase in Astrocytes of Rat Brain,”Brain Research161:303-310, 1979.
Richman, Paul G., et al., “Inhibition of γ-Glutamylcystein Synthetase by L-Methionine-S-Sulfoximine,”J. Biological Chemistry248(19): 6684-6690, 1973.
Rowe, W. Bruce, et al., “Identification of L-Methionine-S-Sulfoximine as the Convulsant Isomer of Methionine Sulfoximine,”Proceedings of the National Academy of Sciences66(2): 500-506, Jun. 1970.
Sellinger, Otto Z., et al., “Methionine Sulfoximine Seizures. VII. the Dissociation of the Convulsant and Glutamine Synthetase Inhibitory Effects,”J. Pharmacology & Experimental Therapeutics161(1): 212-222, 1968.
Sugimoto, Hideyoshi, et al., “Methionine Sulfoximine, a Glutamine Synthetase Inhibitor, Attenuates Increased Extracellular Potassium Activity During Acute Hyperammonemia,”Journal of Cerebral Blood Flow & Metabolism, 17:44-49, 1997.
Takahashi, Hideo, et al., “Inhibition of Brain Glutamine Accumulation Prevents Cerebral Edema in Hyperammonemic Rats,”American Physiological Society261:H825-H829, 1991.
Voorhies, Theresa M., “Acute Hyperammonemia in the Young Primate: Physiologic and Neuropathologic Correlates,”Pediatric Research17(12):970-975, 1983.
Wada, Juhn A., et al., “The Susceptibilty of Auditory Stimuli of Animals Treated with Methionine Sulfoximine,”Experimental Neurology15:157-165, 196.
Warren, Kenneth S., et al., “Effect of an Inhibitor of Glutamine Synthesis (Methionine Sulfoximine) on Ammonia Toxicity and Metabolism,”J. Lab.&Clin. Med. 64(3): 442-449, 1964.
Watson, Alan J., et al. “Transient Idiopathic Hyperammonaemia in Adults,”The Lancet1271-1274, Dec. 7, 1985.
Willard-Mack, C.L., et al., “Inhibition of Glutamine Synthetase Reduces Ammonia-Induced Astrocyte Swelling in Rat,”Neuroscience71(2): 589-599, 1996.
Zwingmann, Claudia, et al., Multinuclear NMR Spectroscopy Studies on NH4CI-Induced 7Metabolic Alterations and Detoxification Processes in Primary Astrocytes and Glioma Cells,Dev. Neurosci20:417-426, 1998.
Apostolakis et al., Brain Research Bulletin, vol. 23, pp. 257-262 (1989).
Ginefri-Gayet et al., Pharmacology Biochemistry and Behavior, vol. 43, pp. 173-179 (1992).
Takahashi et al., Circulation Research, 71(5), 1220-1230 (Nov. 1992).
Harth et al., J. Exp. Med., 189(9), 1425-1435 (May 3, 1999).
Lundgren Jeffrey S.
Odessa Pharma
Rothwell Figg Ernst & Manbeck P.C.
Vakili Zohreh
LandOfFree
Treatment of polyglutamine disorders caused by expanding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of polyglutamine disorders caused by expanding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of polyglutamine disorders caused by expanding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305433